Literature DB >> 3056454

Management of facial spasm with Clostridium botulinum toxin, type A (Oculinum)

A W Biglan1, M May, R A Bowers.   

Abstract

One hundred five patients received 391 graded injections of Clostridium botulinum type A toxin (Oculinum) to treat uncontrollable facial muscle spasm. Patients had essential blepharospasm (n = 61), hemifacial spasm (n = 24), or aberrant regeneration of the seventh cranial nerve (n = 20). Muscle spasms were reduced within two days of the first injection of toxin and, in most cases, the drug effect lasted three to four months. Control of facial muscle spasm was achieved in all patients. Complications related to treatment included transient blepharoptosis (n = 7), diplopia (n = 2), and altered facial expression (n = 11). Systemic side effects were not observed. Select chemodenervation of facial muscles with graded injections of botulinum toxin is a useful adjunct to control blepharospasm, hemifacial spasm, and facial spasm due to aberrant regeneration of the facial nerve.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3056454     DOI: 10.1001/archotol.1988.01860240057024

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  2 in total

1.  Costs of treating dystonias and hemifacial spasm with botulinum toxin A.

Authors:  R C Dodel; A Kirchner; R Koehne-Volland; G Künig; A Ceballos-Baumann; M Naumann; A Brashear; H P Richter; T D Szucs; W H Oertel
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

2.  Pretarsal application of botulinum toxin for treatment of blepharospasm.

Authors:  M Aramideh; B W Ongerboer de Visser; J W Brans; J H Koelman; J D Speelman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-09       Impact factor: 10.154

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.